Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo drug shows promise for Tough-to-Treat hodgkin lymphoma

NCT ID NCT05508867

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 02, 2026 · Updated 3 times

Summary

This phase 2 trial tests a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard chemotherapy in people with classical Hodgkin lymphoma that has come back or stopped responding to treatment. About 200 participants will be randomly assigned to receive either the experimental drug or chemotherapy. The main goal is to see if the new combination helps people live longer without their cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
favezelimab/pembrolizumab (MK-4280A)
What this could lead to
If successful, this could offer a new treatment option for people with classical Hodgkin lymphoma whose cancer has stopped responding to current therapies.
What could go wrong
This is a phase 2 trial, so results are still early. The experimental drug may not work better than chemotherapy, and side effects could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

203 people

The number who actually took part.

Started

Oct 2022

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has histologically confirmed diagnosis of classical Hodgkin lymphoma (cHL) that is 2-fluorodeoxyglucose-avid (FDG-avid). * Has relapsed (defined as disease progression after most recent therapy) or refractory (defined as failed to achieve CR or PR to most recent therapy) cHL and exhausted all available treatment options with known clinical benefit. * Has progressed on treatment with an anti-PD-(L)1 monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. * Submits an archival (≤5 years) or newly obtained tumor tissue sample which has not been previously irradiated. Exclusion Criteria: * Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy. * History of central nervous system (CNS) metastases or active CNS involvement. * Has an active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy. * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * Has an active infection requiring systemic treatment. * History of hemophagocytic lymphohisticytosis. * Has an active seizure disorder that is not well controlled. * Has clinically significant (ie, active) cardiovascular disease. * Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization. * Received prior radiotherapy within 2 weeks of start of study intervention or radiation related toxicities requiring corticosteroids. * Has not adequately recovered from major surgical procedure. * Known additional malignancy that is progressing or has required active treatment within the past 3 years. * History of human immunodeficiency virus (HIV). * Has had an allogeneic hematopoietic stem cell or solid organ transplantation within the last 5 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Classical Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hodgkin lymphoma

Contacts and locations

Locations

  • AHN West Penn Hospital ( Site 2213)

    Pittsburgh, Pennsylvania, 15224, United States

  • Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1900)

    Uppsala, Uppsala County, 751 85, Sweden

  • Anhui Provincial Cancer Hospital ( Site 0501)

    Hefei, Anhui, 230031, China

  • Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 2000)

    Ankara, 06100, Turkey (Türkiye)

  • Antalya Egitim ve Arastırma Hastanesi ( Site 2011)

    Antalya, 07100, Turkey (Türkiye)

  • Asan Medical Center-Department of Oncology ( Site 1703)

    Seoul, 05505, South Korea

  • Beijing Hospital ( Site 0514)

    Beijing, Beijing Municipality, 100005, China

  • CENTRE LEON BERARD-Medical oncology ( Site 0703)

    Lyon, Rhone, 69008, France

  • CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 1812)

    A Coruña, La Coruna, 15006, Spain

  • Cancer and Hematology Centers of Western Michigan ( Site 2222)

    Grand Rapids, Michigan, 49503, United States

  • Carmel Hospital ( Site 1007)

    Haifa, 3436212, Israel

  • Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 0704)

    Limoges, Haute-Vienne, 87042, France

  • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou-haematology ( Site 0707)

    Rennes, Brittany Region, 35033, France

  • Centro de Infusion Superare ( Site 2503)

    Mexico City, Mexico City, 03100, Mexico

  • Clatterbridge Cancer Centre - Liverpool-Heamatology ( Site 2108)

    Liverpool, L7 8YA, United Kingdom

  • Cleveland Clinic-Taussig Cancer Center ( Site 2203)

    Cleveland, Ohio, 44195, United States

  • Clínica Inmunocel ( Site 0407)

    Santiago, Region M. de Santiago, 7580206, Chile

  • Cross Cancer Institute ( Site 0313)

    Edmonton, Alberta, T6G 1Z2, Canada

  • Derriford Hospital ( Site 2107)

    Plymouth, Devon, Pl6 8DH, United Kingdom

  • Ege Universitesi Hastanesi ( Site 2001)

    Izmir, 35100, Turkey (Türkiye)

  • FALP-UIDO ( Site 0400)

    Santiago, Region M. de Santiago, 7500921, Chile

  • Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0902)

    Hradec Králové, 500 05, Czechia

  • Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0901)

    Brno, Brno-mesto, 625 00, Czechia

  • Fred Hutchinson Cancer Center ( Site 2212)

    Seattle, Washington, 98109, United States

  • Fudan University Shanghai Cancer Center ( Site 0520)

    Shanghai, Shanghai Municipality, 200032, China

  • Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 2301)

    Mendoza, M5500AYB, Argentina

  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0202)

    Barretos, São Paulo, 14784400, Brazil

  • GenesisCare - Oxford ( Site 2104)

    Oxford, Oxfordshire, OX4 6LB, United Kingdom

  • HENRI MONDOR HOSPITAL ( Site 0702)

    Créteil, Seine-et-Marne, 94000, France

  • Hacettepe Universite Hastaneleri-Department of Hematology ( Site 2006)

    Ankara, 06230, Turkey (Türkiye)

  • Hadassah Medical Center-Hemato-Oncology ( Site 1000)

    Jerusalem, 9112001, Israel

  • Henan Cancer Hospital ( Site 0515)

    Zhengzhou, Henan, 450008, China

  • Hospital Aleman-oncohematologic diseases ( Site 2302)

    Buenos Aires, C1118AAT, Argentina

  • Hospital General Universitario de Alicante ( Site 1806)

    Alicante, 03010, Spain

  • Hospital Insular de Gran Canaria-Oncology ( Site 1807)

    Las Palmas de Gran Canaria, Las Palmas, 35016, Spain

  • Hospital Paulistano-Americas Oncologia ( Site 0207)

    São Paulo, 01321-001, Brazil

  • Hospital Universitari Vall d'Hebron ( Site 1803)

    Barcelona, Catalonia, 08035, Spain

  • Hospital Universitario 12 de Octubre-Hemathology and hemotherapy ( Site 1810)

    Madrid, 28041, Spain

  • Hospital Universitario Marqués de Valdecilla ( Site 1805)

    Santander, Cantabria, 39008, Spain

  • Hospital Universitario Virgen de la Victoria ( Site 1808)

    Málaga, 29010, Spain

  • Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 1801)

    Salamanca, 37007, Spain

  • Hunan Cancer Hospital ( Site 0503)

    Changsha, Hunan, 410013, China

  • Institut Curie - site Saint-Cloud ( Site 0708)

    Saint-Cloud, Hauts-de-Seine, 92210, France

  • Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE ( Site 0706)

    Toulouse, Haute-Garonne, 31059, France

  • Jewish General Hospital ( Site 0309)

    Montreal, Quebec, H3T 1E2, Canada

  • Johns Hopkins University-The Sidney Kimmel Comprehensive Cancer Center ( Site 2206)

    Baltimore, Maryland, 21231, United States

  • Klinikum Stuttgart - Katharinenhospital ( Site 0804)

    Stuttgart, Baden-Wurttemberg, 70174, Germany

  • Kocaeli Üniversitesi-Hematology ( Site 2009)

    Kocaeli, 41380, Turkey (Türkiye)

  • Leicester Royal Infirmary ( Site 2100)

    Leicester, LE1 5WW, United Kingdom

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site

    Torrance, California, 90502, United States

  • McGill University Health Centre ( Site 0314)

    Montreal, Quebec, H4A 3J1, Canada

  • Mega Medipol-Hematology ( Site 2005)

    Stanbul, Istanbul, 34214, Turkey (Türkiye)

  • Moffitt Cancer Center ( Site 2200)

    Tampa, Florida, 33612, United States

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Ningbo First Hospital ( Site 0518)

    Ningbo, Zhejiang, 315010, China

  • Ospedale Regionale Bellinzona e Valli-IOSI ( Site 1600)

    Bellinzona, Canton Ticino, 6501, Switzerland

  • Peking University Third Hospital-Hematology ( Site 0519)

    Beijing, Beijing Municipality, 100091, China

  • Princess Margaret Cancer Centre ( Site 0310)

    Toronto, Ontario, M5G 2M9, Canada

  • Pusan National University Hospital-Internal Medicine ( Site 1704)

    Busan, Pusan-Kwangyokshi, 49241, South Korea

  • Rabin Medical Center-Hemato-Oncology ( Site 1001)

    Petah Tikva, 4910021, Israel

  • Rambam Health Care Campus ( Site 1004)

    Haifa, 3109601, Israel

  • Roswell Park Cancer Institute ( Site 2220)

    Buffalo, New York, 14263, United States

  • Royal Adelaide Hospital ( Site 0005)

    Adelaide, South Australia, 5000, Australia

  • Royal Perth Hospital-Haematology ( Site 0004)

    Perth, Western Australia, 6000, Australia

  • Rutgers Cancer Institute of New Jersey ( Site 2217)

    New Brunswick, New Jersey, 08903, United States

  • Samsung Medical Center ( Site 1700)

    Seoul, 06351, South Korea

  • Seoul National University Hospital ( Site 1701)

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1702)

    Seoul, 03722, South Korea

  • Sheba Medical Center-Hemato Oncology ( Site 1005)

    Ramat Gan, 5265601, Israel

  • Skånes Universitetssjukhus Lund ( Site 1901)

    Lund, Skåne County, 22185, Sweden

  • Sourasky Medical Center ( Site 1002)

    Tel Aviv, 6423906, Israel

  • St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 2105)

    London, London, City of, EC1A 7BE, United Kingdom

  • St James's University Hospital ( Site 2109)

    Leeds, LS9 7TF, United Kingdom

  • Sun Yat-sen University Cancer Center ( Site 0500)

    Guangzhou, Guangdong, 510060, China

  • Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S

    Kielce, Świętokrzyskie Voivodeship, 25-734, Poland

  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie-Oncology Department ( Site 1406)

    Krakow, Lesser Poland Voivodeship, 31-826, Poland

  • The Beatson West of Scotland Cancer Centre ( Site 2110)

    Glasgow, Glasgow City, G12 0YN, United Kingdom

  • The First Affiliated hospital of Xiamen University ( Site 0512)

    Xiamen, Fujian, 361003, China

  • The First Hospital of Jilin University-Hematology ( Site 0516)

    Changchun, Jilin, 130021, China

  • The Townsville Hospital ( Site 0006)

    Townsville, Queensland, 4814, Australia

  • The University of Arizona Cancer Center - North Campus ( Site 2216)

    Tucson, Arizona, 85719, United States

  • Tianjin Medical University Cancer Institute & Hospital-lymphoma ( Site 0506)

    Tianjin, Tianjin Municipality, 300060, China

  • UCLA Hematology/Oncology - Santa Monica ( Site 2208)

    Los Angeles, California, 90404, United States

  • UPMC Hillman Cancer Center ( Site 2205)

    Pittsburgh, Pennsylvania, 15232, United States

  • UZ Leuven-Hematology ( Site 0101)

    Leuven, Vlaams-Brabant, 3000, Belgium

  • Unidad Médica Onco-hematológica ( Site 2507)

    Puebla City, 72424, Mexico

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0509)

    Wuhan, Hubei, 430010, China

  • Universitaetsklinikum Carl Gustav Carus Dresden-University Cancer Center Early Clinical Trial Unit (

    Dresden, Saxony, 01307, Germany

  • Universitaetsklinikum Essen ( Site 0807)

    Essen, North Rhine-Westphalia, 45147, Germany

  • Universitaetsklinikum Koeln-Klinik I für Innere Medizin ( Site 0801)

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Universitaetsklinikum Ulm-Department of Internal Medicine III ( Site 0805)

    Ulm, Baden-Wurttemberg, 89081, Germany

  • University Hospitals Cleveland Medical Center ( Site 2214)

    Cleveland, Ohio, 44106, United States

  • University of Kentucky Chandler Medical Center ( Site 2201)

    Lexington, Kentucky, 40536, United States

  • University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 2210)

    Baltimore, Maryland, 21201, United States

  • University of Michigan ( Site 2215)

    Ann Arbor, Michigan, 48109, United States

  • Universitätsklinikum Leipzig ( Site 0803)

    Leipzig, Saxony, 04103, Germany

  • Universitätsklinikum Münster - Albert Schweitzer Campus ( Site 0806)

    Münster, North Rhine-Westphalia, 48149, Germany

  • Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi

    Namur, 5530, Belgium

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckieg-Klinika Hematologii, Nowotworów Krwi i

    Wroclaw, Lower Silesian Voivodeship, 50-556, Poland

  • Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 1402)

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

  • Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0903)

    Prague, 128 08, Czechia

  • West China Hospital of Sichuan University-Head and Neck Oncology ( Site 0502)

    Chengdu, Sichuan, 610041, China

  • Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 0002)

    St Albans, Victoria, 3021, Australia

  • Xiangya Hospital Central South University ( Site 0513)

    Changsha, Hunan, 410008, China

  • Zhejiang Cancer Hospital ( Site 0510)

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.